From One Hormone to Eighty: The Slow Arithmetic of Peptide Medicines Since 1923
Two names on a 1923 prize, not four
The 1923 Nobel Prize in Physiology or Medicine went to Frederick Banting and John Macleod for the discovery of insulin, a decision that still causes arguments because two other researchers, Charles Best and James Collip, did much of the laboratory work but were left off the citation.
That split matters for how the history of peptide medicine gets told. The prize fixed 1923 as the symbolic birth date of the field, even though the therapy itself had already moved from laboratory to patient the year before.
Insulin's early history is a reminder that regulatory and scientific recognition do not always arrive at the same moment, or go to the same people.
Why reviewers date the field to the 1920s, not 1923
A 2018 review in a peptide therapeutics journal dates the field of therapeutic peptides from the advent of insulin therapy in the 1920s, not from the Nobel Prize itself.
That distinction is deliberate. The 1920s marks when insulin began reaching patients as a manufactured product, a practical starting point for a drug class, separate from the prize that recognised the underlying discovery.
The same 2018 review counts over 60 approved peptide drugs by that year, which means it took roughly nine decades to go from one hormone to five dozen distinct medicines.
What changed between 2018 and 2021
By 2021 a review in Nature Reviews Drug Discovery counted more than 80 peptide drugs on the market, up from the more than 60 recorded in the 2018 review.
That is a gain of roughly 20 approved peptide medicines in about three years, a much faster rate than the decades it took to reach the first few dozen.
The pattern fits a common shape in drug development: a long period where a single discovery, insulin, stands almost alone, followed by a cluster of approvals once manufacturing, chemistry and regulatory pathways for peptides become routine.
What counts as a peptide drug, and who can prescribe one
Peptide drugs are built from short chains of amino acids, the same building blocks as proteins, but shorter and often simpler to manufacture than a full protein like an antibody.
Insulin itself is a peptide hormone, and its success as a manufactured medicine in the 1920s is part of why later peptide chemistry attracted investment and regulatory attention.
Most peptides available as medicines are prescription-only in Australia, meaning a qualified prescriber decides whether a particular peptide drug is appropriate for a particular patient.
The TGA states that medicines must go through its evaluation process before they can be supplied in Australia, and being structurally similar to insulin does not make a newer peptide automatically approved or appropriate for any particular use.
Reading the count correctly
The jump from over 60 in 2018 to more than 80 in 2021 is a count of drugs reaching markets somewhere in the world, not a count of drugs approved in Australia specifically.
Anyone comparing these figures to what is available locally needs to check the TGA's own register rather than assume international approval numbers apply directly.
The gap between a peptide being discovered, like insulin in the 1920s, and a peptide being approved for general use can still span years of trials, even in an era when the pace of new peptide approvals has picked up.
Most peptides are prescription-only medicines in Australia. This article reports published research and regulation for general education and is not medical advice. Speak to your doctor.
Sources
- The Nobel Prize in Physiology or Medicine 1923: Banting and Macleod, for the discovery of insulin
- Therapeutic peptides: historical perspectives, current development trends, and future directions (Bioorganic & Medicinal Chemistry, 2018)
- Trends in peptide drug discovery (Nature Reviews Drug Discovery, 2021)